Bridgefront Capital’s Pacira BioSciences PCRX Stock Holding History

Bridgefront Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,240	Closed	-$336K	–	616
2023 Q1	$336K	Buy	+8,240	New	+$328K	0.21%	184
2021 Q2	–	Sell	-4,445	Closed	-$312K	–	828
2021 Q1	$312K	Buy	+4,445	New	+$318K	0.1%	414

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bridgefront Capital's PCRX Position: Q2 2023 in Review

Bridgefront Capital sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 8,240 shares — an estimated $336K sold.

Bridgefront Capital first reported a position in PCRX in Q1 2021 and held it in 2 quarters. The position peaked at $336K in Q1 2023. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Bridgefront Capital reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Bridgefront Capital sold 8,240 Pacira BioSciences shares in Q2 2023, an estimated $336K.
Bridgefront Capital first reported a position in Pacira BioSciences in Q1 2021 and held it in 2 quarters.
Bridgefront Capital's Pacira BioSciences position peaked at $336K in Q1 2023.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Bridgefront Capital's 13F filing for Q2 2023, filed 14 Aug 2023.